SYN-010

Theriva Biologics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SYN-010
Sponsor	Theriva Biologics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of SYN-010 in IBS-C (PHASE2)
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block (PHASE1)
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C (PHASE2)
A Study of the Effect of SYN-010 on Subjects With IBS-C (PHASE2)
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYN-010 CI brief — competitive landscape report
SYN-010 updates RSS · CI watch RSS
Theriva Biologics, Inc. portfolio CI